Novametrix
This article was originally published in The Gray Sheet
Executive Summary
Shipments of the MARSpo2 Tech pulse oximeter are expected to commence "sometime in the late spring," the firm states following FDA market go-ahead, announced March 2. The Motion Object Rejection System (MARS) improves pulse oximetry performance on patients who experience significant motion or who are poorly perfused, the firm claims